NYSE:RCUS | Free Cash Flow | Arcus Biosciences, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2016-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$138M$0.00-$138M
2025-12-31-$120M$1M-$121M
2025-03-31-$132M$1M-$133M
2024-12-31-$100M$1M-$101M
2024-03-31-$2M$4M-$6M
2023-12-31-$88M$6M-$94M
2023-03-31-$98M$3M-$101M
2022-12-31-$70M$0.00-$70M
2022-03-31$654M$3M$651M
2021-12-31-$61.93M$8.43M-$70.36M-25.17%
2021-03-31-$66.32M$3.64M-$69.96M
2020-12-31-$50.05M$1.46M-$51.51M
2020-03-31-$31.28M$209,000.00-$31.49M
2019-12-31-$9.47M$196,000.00-$9.67M
2019-03-31-$16.84M$628,000.00-$17.47M
2018-12-31-$7.11M$258,000.00-$7.37M
2018-03-31-$13.25M$1.05M-$14.3M
2017-12-31$15.59M$294,000.00$15.29M
2017-03-31-$9.6M$2.14M-$11.74M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$482M$2M-$484M
2024-12-31-$170M$6M-$176M
2023-12-31-$306M$24M-$330M
2022-12-31$438M$6M$432M
2021-12-31-$256M$26M-$282M-532.08%
2020-12-31$111M$3M$108M
2019-12-31-$73.46M$1.93M-$75.39M
2018-12-31-$43M$3.74M-$46.74M
2017-12-31-$25.06M$5.51M-$30.57M
2016-12-31-$12.94M$4.1M-$17.04M